Phospholamban antibody (pSer16) (PE)
Quick Overview for Phospholamban antibody (pSer16) (PE) (ABIN2178506)
Target
See all Phospholamban (PLN) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- pSer16
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16
-
Isotype
- IgG
-
-
-
-
Application Notes
-
FCM: (1:20-100)
Optimal working dilution should be determined by the investigator. -
Comment
-
Exitation/Emission: 480,565nm/578nm
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 100 μg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at 4 °C for 12 months.
-
-
- Phospholamban (PLN)
-
Alternative Name
- Plb
-
Background
-
Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Synonyms: Phospholamban phospho S16, p-Phospholamban phospho S16, p-PLBS16, Cardiac phospholamban, CMD1P, PLB, PLN, PPLA_HUMAN. -
Gene ID
- 5350
-
Pathways
- Negative Regulation of Transporter Activity
Target
-